Cargando…
South African experts comment on FDA approval of dabigatran inatrial fibrillation
Autores principales: | E, Klug, A, Bryer, J, Aalbers |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Clinics Cardive Publishing
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6053645/ https://www.ncbi.nlm.nih.gov/pubmed/21298209 |
Ejemplares similares
-
FDA committee unanimously recommends approval of dabigatran etexilate for stroke prevention in atrial fibrillation
por: J, Aalbers, et al.
Publicado: (2010) -
New anti–coagulant therapies set to revitalise clinical haemotology practice
por: J, AALBERS, et al.
Publicado: (2010) -
Thrombolysis risk prediction: applying the SITS-SICH and SEDAN scores
in South African patients
por: von Klemperer, A, et al.
Publicado: (2014) -
Boehringer launches first direct thrombin inhibitor: dabigatran (Pradaxa®)
Publicado: (2010) -
Left atrial appendage closure in patients with atrial fibrillation in whom warfarin is contra-indicated: initial South African experience
por: Abelson, Mark
Publicado: (2013)